Neurocrine Biosciences vs its peers
The 10 largest Biotechnology companies by market value, prices of Nov 20, 2026
Neurocrine Biosciences is the 10th largest of the 10 biggest Biotechnology companies on OQRO by market value, at $15.2B. Its revenue of $2.86B in fiscal 2025 ranks 8th of 10. It keeps 22% of revenue as operating profit, 8th of 9 (median 29%). Revenue grew 21% on the year before, against a median of +8.0%. At 31.8x its latest annual earnings, the market prices it above its peers (median 22.6x).
Side by side
| Company | Market value | Revenue | Growth y/y | 5-yr growth / yr | Gross margin | Operating margin | Net margin | Free cash flow margin | R&D / revenue | Price / earnings | Price / sales | FCF yield | Stock, 12 months |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AmgenAMGN · FY2025 | $236B | $36.8B | +10.0% | +7.6% | 67.2% | 24.7% | 21.0% | 22.0% | 19.8% | 30.6x | 6.4x |
Each company’s latest fiscal year (FY), so the years can end a few months apart. Price ratios divide today’s market value by that year’s figure; price / earnings is left out on a loss. “—” means the company did not tag that line in its annual report.
Operating margin
- UTHR47%
- EXEL38%
- VRTX35%
- GILD34%
- INCY29%
- REGN25%
- AMGN25%
- NBIX22%
- MRNA−158%
Compare Neurocrine Biosciences head to head
Where Neurocrine Biosciences’s revenue comes from and where it goes: Neurocrine Biosciences revenue breakdown. Twenty years of results: Neurocrine Biosciences financial history.
Common questions
Who are Neurocrine Biosciences's competitors?
The largest companies in its industry (Biotechnology) by market value: Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Moderna (MRNA), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY) and Exelixis (EXEL). They share Neurocrine Biosciences's industry listing; not every one competes with it on every product.
Is Neurocrine Biosciences bigger than Amgen?
No, by market value: Neurocrine Biosciences is worth $15.2B and Amgen $236B. By revenue, Neurocrine Biosciences brought in $2.86B in fiscal 2025 and Amgen $36.8B in fiscal 2025.
How does Neurocrine Biosciences's valuation compare with its peers?
Where these figures come from
The group is the companies OQRO lists in the same industry as Neurocrine Biosciences (Biotechnology), the largest 9 by market value, plus Neurocrine Biosciences. Companies whose latest annual report is more than a year and a half old, or that report in a currency other than the dollar, are left out.
Revenue, operating income, net income, gross profit, research and development and free cash flow (cash from operations minus capital expenditure) are each company’s own full-year lines from its latest 10-K, as tagged in XBRL (SEC companyfacts). Market value is the last close times the shares outstanding on the latest filing. Price / earnings is market value over net income; price / sales is market value over revenue; free cash flow yield is free cash flow over market value. Five-year growth is the yearly rate that takes revenue from five fiscal years before to the latest. This page describes the past and is not investment advice. No language model wrote it.









